Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if his Department will (a) collect and (b) publish data on the (i) prevalence, (ii) diagnosis and (iii) treatment of PCOS in England.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Polycystic ovary syndrome (PCOS) is a condition that can be diagnosed in multiple different ways, including without a diagnosis code and in primary care settings, and therefore it is very difficult to identify the number of specific diagnostic tests carried out overall.
However, the diagnosis code for PCOS is recorded in the Hospital Episode Statistics (HES) dataset. The number of patients treated in secondary care where the primary diagnosis is PCOS is as follows:
The most recent publications for outpatient and admitted activity in 2023/24, namely the Hospital Admitted Patient Care Activity Diagnosis 2023 to 2024 table and the Outpatient Primary Diagnosis by Attendance Type 2023 to 2024 table, have been placed in the Library due to the size of the data.
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the potential merits of expanding investment in mental health support and screening within PCOS treatment plans.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
While we have no plans at present to make such an assessment, we know that more needs to be done to support women with gynaecological conditions, such as polycystic ovary syndrome (PCOS). The Government is committed to prioritising women’s health as we reform the National Health Service.
The 10-Year Health Plan sets out ambitious plans to boost mental health support and to provide the right support at the right time to the right people, including women with PCOS. We are transforming mental health services into 24/7 neighbourhood mental health centres, expanding talking therapies, and giving patients better access to 24/7 support directly through the NHS App, including self-referral for talking therapies.
For 2025/26, mental health spending is forecast to amount to £15.6 billion. This represents a significant uplift of £688 million in real terms spending on mental health compared to the previous financial year.
In the Spending Review announcement, we have confirmed that we will fulfil our commitment to recruit an additional 8,500 mental health workers for children and adults by the end of this Parliament. 6,700 of these workers have been recruited since July, meaning we are more than halfway towards our target.
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has considered prioritising the integration of PCOS care into Women's Health Hubs.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Women’s health hubs bring together healthcare professionals and existing services to provide integrated women’s health services in the community, centred on meeting women’s needs across their life course.
As set out in the core specification on the GOV.UK website, women’s health hubs should provide assessment and treatment for menstrual problems, including but not limited to care for heavy, painful, or irregular menstrual bleeding, and care for conditions such as polycystic ovary syndrome.
We are looking to integrated care boards to further expand their coverage of women’s health hubs to improve local delivery of services to women. We will support them in doing so, drawing on the learning from the existing women’s health hubs.
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that new NICE guidelines on PCOS are embedded in a nationally commissioned diagnostic pathway to reduce diagnostic delays.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) has not yet published its clinical guideline on the assessment and management of polycystic ovary syndrome. The guideline is currently in development and NICE expects to publish the final guideline in November 2026. Once published, National Health Service commissioners will be expected to take the guideline fully into account in designing services that meet the needs of their local populations.
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with owners of defibrillators on encouraging them to register the defibrillators on The Circuit.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department has not held any discussions with the owners or guardians of defibrillators. Publicly accessible defibrillators owned by local community organisations are acquired through a variety of means. This can include applying for one from a charity operated fund, purchasing one directly from a charity, or purchasing one as a private purchase. It is not uncommon for charities supplying defibrillators through a fund to require those defibrillators to be registered on The Circuit. Defibrillator charities also promote The Circuit on their website.
There is no registry or database of defibrillator purchases in England, and it would not be appropriate for the Department to have access to the personal information of the people who purchase these devices. Therefore, it is not possible for the Department to contact people who have purchased a defibrillator privately, be it through a charity or from a private company.
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the potential implications for his policies of trends in the rate of community pharmacy closures in England.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government has been clear that community pharmacies will have a vital role in the Neighbourhood Health Service, bringing healthcare to the heart of the high street, as set out in our 10-Year Health Plan.
There are over 10,400 pharmacies in England. Despite a reduction in the number of pharmacies, access to pharmacies remains good. Over 80% of the population live within one mile of a pharmacy and there are twice as many pharmacies in the most deprived areas. In some rural areas where there is no pharmacy, general practitioners are permitted to dispense medicines to their patients. Patients can also choose to access medicines and pharmacy services through any of the over 400 National Health Service online pharmacies that are contractually required to deliver medicines they dispense free of charge to patients.
For 2025/26, funding for the core community pharmacy contractual framework has been increased to £3.073 billion. This represents the largest uplift in funding of any part of the NHS, over 19% across 2024/25 and 2025/26. There is also additional funding available, for example for pharmacies delivering Pharmacy First consultations and flu and COVID-19 vaccinations.
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help support the long-term (a) financial and (b) operational sustainability of community pharmacies.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government has been clear that community pharmacies will have a vital role in the Neighbourhood Health Service, bringing healthcare to the heart of the high street, as set out in our 10-Year Health Plan.
There are over 10,400 pharmacies in England. Despite a reduction in the number of pharmacies, access to pharmacies remains good. Over 80% of the population live within one mile of a pharmacy and there are twice as many pharmacies in the most deprived areas. In some rural areas where there is no pharmacy, general practitioners are permitted to dispense medicines to their patients. Patients can also choose to access medicines and pharmacy services through any of the over 400 National Health Service online pharmacies that are contractually required to deliver medicines they dispense free of charge to patients.
For 2025/26, funding for the core community pharmacy contractual framework has been increased to £3.073 billion. This represents the largest uplift in funding of any part of the NHS, over 19% across 2024/25 and 2025/26. There is also additional funding available, for example for pharmacies delivering Pharmacy First consultations and flu and COVID-19 vaccinations.
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that patients have timely access to pharmacy services in areas where community pharmacies have closed.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government has been clear that community pharmacies will have a vital role in the Neighbourhood Health Service, bringing healthcare to the heart of the high street, as set out in our 10-Year Health Plan.
There are over 10,400 pharmacies in England. Despite a reduction in the number of pharmacies, access to pharmacies remains good. Over 80% of the population live within one mile of a pharmacy and there are twice as many pharmacies in the most deprived areas. In some rural areas where there is no pharmacy, general practitioners are permitted to dispense medicines to their patients. Patients can also choose to access medicines and pharmacy services through any of the over 400 National Health Service online pharmacies that are contractually required to deliver medicines they dispense free of charge to patients.
For 2025/26, funding for the core community pharmacy contractual framework has been increased to £3.073 billion. This represents the largest uplift in funding of any part of the NHS, over 19% across 2024/25 and 2025/26. There is also additional funding available, for example for pharmacies delivering Pharmacy First consultations and flu and COVID-19 vaccinations.
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to review the manner in which NICE considers carer-related quality of life in its assessments of treatments for (a) rare, (b) progressive and (c) paediatric diseases.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence’s (NICE) technology appraisal process allows its independent committees to take societal benefits, such as health-related quality-of-life for carers and impacts on personal social services, into account. NICE’s methods are set out in its published health technology evaluations manual, which is available at the following link:
https://www.nice.org.uk/process/pmg36
Evaluations should consider all health effects for patients, and, when relevant, carers. When presenting health effects for carers, evidence should show when the condition is associated with a substantial effect on a carer’s health-related quality of life and how the technology affects carers. This applies for all therapies, including therapies for rare diseases. NICE appraisals specifically consider health-related quality of life, for both patients and carers, rather than quality of life as a whole.
Asked by: Amanda Hack (Labour - North West Leicestershire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that the potential impact on carers is taken into account in NICE’s health technology appraisal decisions.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The National Institute for Health and Care Excellence’s (NICE) technology appraisal process allows its independent committees to take societal benefits, such as health-related quality-of-life for carers and impacts on personal social services, into account. NICE’s methods are set out in its published health technology evaluations manual, which is available at the following link:
https://www.nice.org.uk/process/pmg36
Evaluations should consider all health effects for patients, and, when relevant, carers. When presenting health effects for carers, evidence should show when the condition is associated with a substantial effect on a carer’s health-related quality of life and how the technology affects carers. This applies for all therapies, including therapies for rare diseases. NICE appraisals specifically consider health-related quality of life, for both patients and carers, rather than quality of life as a whole.